Abbott Laboratories (ABT) : Boston Financial Mangement scooped up 133,211 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 321,742 shares of Abbott Laboratories which is valued at $14,491,260.Abbott Laboratories makes up approximately 1.14% of Boston Financial Mangement’s portfolio.
Other Hedge Funds, Including , United Services Automobile Association boosted its stake in ABT in the latest quarter, The investment management firm added 22,831 additional shares and now holds a total of 613,401 shares of Abbott Laboratories which is valued at $27,627,581. Abbott Laboratories makes up approx 0.09% of United Services Automobile Association’s portfolio.Intrust Bank Na boosted its stake in ABT in the latest quarter, The investment management firm added 2,547 additional shares and now holds a total of 21,948 shares of Abbott Laboratories which is valued at $986,563. Abbott Laboratories makes up approx 0.39% of Intrust Bank Na’s portfolio.Everett Harris Co Ca boosted its stake in ABT in the latest quarter, The investment management firm added 159,608 additional shares and now holds a total of 1,696,777 shares of Abbott Laboratories which is valued at $76,270,126. Abbott Laboratories makes up approx 2.65% of Everett Harris Co Ca’s portfolio.Shinko Asset Management Ltd. reduced its stake in ABT by selling 133 shares or 3.41% in the most recent quarter. The Hedge Fund company now holds 3,770 shares of ABT which is valued at $162,751.Stralem Co Inc reduced its stake in ABT by selling 25,300 shares or 6.04% in the most recent quarter. The Hedge Fund company now holds 393,665 shares of ABT which is valued at $16,789,812. Abbott Laboratories makes up approx 1.90% of Stralem Co Inc’s portfolio.
Abbott Laboratories closed down -0.27 points or -0.61% at $43.9 with 74,01,381 shares getting traded on Tuesday. Post opening the session at $44.37, the shares hit an intraday low of $43.9 and an intraday high of $44.42 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Abbott Laboratories reported $0.55 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 20, 2016. Analyst had a consensus of $0.53. The company had revenue of $5333.00 million for the quarter, compared to analysts expectations of $5244.94 million. The company’s revenue was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.52 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Abbott Laboratories was Upgraded by Edward Jones to ” Buy” on Jun 21, 2016.
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.